| Literature DB >> 26876595 |
N M Anderson1, D Li1, H L Peng2,3, F J F Laroche1, M R Mansour2, E Gjini2, M Aioub1, D J Helman2, J E Roderick4, T Cheng1, I Harrold1, Y Samaha1, L Meng1, A Amsterdam5, D S Neuberg6, T T Denton7, T Sanda8, M A Kelliher4, A Singh1, A T Look2, H Feng1.
Abstract
Despite the pivotal role of MYC in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) and many other cancers, the mechanisms underlying MYC-mediated tumorigenesis remain inadequately understood. Here we utilized a well-characterized zebrafish model of Myc-induced T-ALL for genetic studies to identify novel genes contributing to disease onset. We found that heterozygous inactivation of a tricarboxylic acid (TCA) cycle enzyme, dihydrolipoamide S-succinyltransferase (Dlst), significantly delayed tumor onset in zebrafish without detectable effects on fish development. DLST is the E2 transferase of the α-ketoglutarate (α-KG) dehydrogenase complex (KGDHC), which converts α-KG to succinyl-CoA in the TCA cycle. RNAi knockdown of DLST led to decreased cell viability and induction of apoptosis in human T-ALL cell lines. Polar metabolomics profiling revealed that the TCA cycle was disrupted by DLST knockdown in human T-ALL cells, as demonstrated by an accumulation of α-KG and a decrease of succinyl-CoA. Addition of succinate, the downstream TCA cycle intermediate, to human T-ALL cells was sufficient to rescue defects in cell viability caused by DLST inactivation. Together, our studies uncovered an important role for DLST in MYC-mediated leukemogenesis and demonstrated the metabolic dependence of T-lymphoblasts on the TCA cycle, thus providing implications for targeted therapy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26876595 PMCID: PMC4889531 DOI: 10.1038/leu.2016.26
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528